Bulk Manufacturer of Controlled Substances Application: Noramco, 8153-8154 [2025-01710]

Download as PDF 8153 Federal Register / Vol. 90, No. 15 / Friday, January 24, 2025 / Notices Register pursuant to section 6(b) of the Act on February 6, 2024 (89 FR 8243). The last notification was filed with the Department on April 16, 2024. A notice was published in the Federal Register pursuant to section 6(b) of the Act on June 28, 2024 (89 FR 54041). Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. The last notification was filed with the Department on July 9, 2024. A notice was published in the Federal Register pursuant to section 6(b) of the Act on September 26, 2024 (89 FR 78900). Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. BILLING CODE P DEPARTMENT OF JUSTICE Antitrust Division Antitrust Division khammond on DSK9W7S144PROD with NOTICES Notice Pursuant to the National Cooperative Research and Production Act of 1993—Undersea Technology Innovation Consortium Notice is hereby given that, on October 10, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Undersea Technology Innovation Consortium (‘‘UTIC’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, The Mason and Hanger Group, Inc., Lexington, KY; EIZO Rugged Solutions, Inc., Orlando, FL; Carnegie Mellon University, Pittsburgh, PA; KAIROS, Inc., California, MD; Seemann Composites LLC, Gulfport, MS; Bishop Ascendant, Inc., Caldwell, NJ; and Calspan Systems LLC, Newport News, VA, have been added as parties to this venture. Also, iXblue Defense Systems, Inc., Lincoln, RI; Integrated Consultants, Inc., San Diego, CA; SubUAS LLC, Bridgewater, NJ; and Basic Engineering Concepts & Technologies, Inc., White Stone, VA, have withdrawn as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and UTIC intends to file additional written notifications disclosing all changes in membership. On October 9, 2018, UTIC filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on November 2, 2018 (83 FR 55203). VerDate Sep<11>2014 16:21 Jan 23, 2025 Jkt 265001 Notice Pursuant to the National Cooperative Research and Production Act of 1993—Consortium for Rare Earth Technologies Notice is hereby given that, on October 11, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Consortium for Rare Earth Technologies (‘‘CREaTe’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Alaska Range Resources, LLC, Palmer, AK; and Orojo Resources USA, LLC, Cleveland, GA, have been added as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open and CREaTe intends to file additional written notifications disclosing all changes in membership. On April 22, 2022, CREaTe filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on May 13, 2022 (87 FR 29384). The last notification was filed with the Department on July 18, 2024. A notice was published in the Federal Register pursuant to section 6(b) of the Act on October 11, 2024 (89 FR 82629). Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. [FR Doc. 2025–01701 Filed 1–23–25; 8:45 am] BILLING CODE P PO 00000 Frm 00039 [Docket No. DEA–1480] Bulk Manufacturer of Controlled Substances Application: Noramco Drug Enforcement Administration, Justice. ACTION: Notice of application. Noramco has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before March 25, 2025. Such persons may also file a written request for a hearing on the application on or before March 25, 2025. ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on October 8, 2024, Noramco, 500 Swedes Landing Road, Wilmington, Delaware 19801–4417, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): SUMMARY: BILLING CODE P DEPARTMENT OF JUSTICE Drug Enforcement Administration AGENCY: [FR Doc. 2025–01704 Filed 1–23–25; 8:45 am] [FR Doc. 2025–01714 Filed 1–23–25; 8:45 am] DEPARTMENT OF JUSTICE Fmt 4703 Sfmt 4703 Controlled substance Gamma Hydroxybutyric Acid. Marihuana ........................ Tetrahydrocannabinols .... Dihydromorphine ............. Hydromorphinol ............... Amphetamine .................. Lisdexamfetamine ........... Methylphenidate .............. Nabilone .......................... Codeine ........................... E:\FR\FM\24JAN1.SGM 24JAN1 Drug code Schedule 2010 I 7360 7370 9145 9301 1100 1205 1724 7379 9050 I I I I II II II II II 8154 Federal Register / Vol. 90, No. 15 / Friday, January 24, 2025 / Notices Controlled substance Drug code Schedule 9120 9143 9150 9193 9250 9300 9330 9333 9610 9620 9630 9639 9640 9652 9668 9780 II II II II II II II II II II II II II II II II DEPARTMENT OF JUSTICE Drug Enforcement Administration Dihydrocodeine ................ Oxycodone ...................... Hydromorphone ............... Hydrocodone ................... Methadone ...................... Morphine .......................... Oripavine ......................... Thebaine .......................... Opium extracts ................ Opium fluid extract .......... Opium tincture ................. Opium, powdered ............ Opium, granulated ........... Oxymorphone .................. Noroxymorphone ............. Tapentadol ...................... [Docket No. DEA–1478] Importer of Controlled Substances Application: VHG Labs DBA LGC Standards Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: The company plans to bulk manufacture the listed controlled substances as an Active Pharmaceutical Ingredient for supply to its customers. In reference to drug codes 7360 (Marihuana), and 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetic. No other activities for these drug codes are authorized for this registration. Matthew Strait, Deputy Assistant Administrator. [FR Doc. 2025–01710 Filed 1–23–25; 8:45 am] BILLING CODE P VHG Labs DBA LGC Standards has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before February 24, 2025. Such persons may also file a written request for a hearing on the application on or before February 24, 2025. ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for SUMMARY: lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on November 1, 2024, VHG Labs dba LGC Standards, 3 Perimeter Road, Manchester, New Hampshire 03103–3341, applied to be registered as an importer of the following basic class(es) of controlled substance(s): khammond on DSK9W7S144PROD with NOTICES Controlled substance Drug code Amineptine (7-[(10,11-dihydro-5Hdibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid) ....................................................... Mesocarb (N-phenyl-N′-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate) ............................................. 3-Fluoro-N-methylcathinone (3-FMC) .................................................................................................................................... Cathinone .............................................................................................................................................................................. Methcathinone ....................................................................................................................................................................... 4-Fluoro-N-methylcathinone (4-FMC) 1238 I N .................................................................................................................... Para-Methoxymethamphetamine (PMMA), 1-(4-methoxyphenyl)-N-methylpropan-2-amine ................................................ Pentedrone (a-methylaminovalerophenone) ......................................................................................................................... Mephedrone (4-Methyl-N-methylcathinone) .......................................................................................................................... 4-Methyl-N-ethylcathinone (4-MEC) ...................................................................................................................................... Naphyrone ............................................................................................................................................................................. N-Ethylamphetamine ............................................................................................................................................................. Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine) 1478 I N ............................................................................. N,N-Dimethylamphetamine .................................................................................................................................................... Fenethylline ........................................................................................................................................................................... Aminorex ................................................................................................................................................................................ 4-Methylaminorex (cis isomer) .............................................................................................................................................. 4,4′-Dimethylaminorex (4,4′-DMAR; 4,5-dihydro-4-1595 I N methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl-5-(4methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine). Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-yl)acetate) ...................................................................................................... Gamma Hydroxybutyric Acid ................................................................................................................................................. Methaqualone ........................................................................................................................................................................ Mecloqualone ........................................................................................................................................................................ Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine ...................................... Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4Hbenzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine) .................................. Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4Hbenzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine ......................................... Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine ................................. Diclazepam (7-chloro-5-(2-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one ...................... JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) .......................................................................................................... SR-18 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) .............................................................................................. ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ................... 5-Fluoro-UR-144 and XLR11 [1-(5-Fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone ....................... AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ............................ 1-(4-Fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanon ........................................................................ VerDate Sep<11>2014 16:21 Jan 23, 2025 Jkt 265001 PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 E:\FR\FM\24JAN1.SGM 24JAN1 Schedule 1219 1227 1233 1235 1237 1238 1245 1246 1248 1249 1258 1475 1478 1480 1503 1585 1590 1595 I I I I I I I I I I I I I I I I I I 1727 2010 2565 2572 2780 2785 2786 2788 2789 6250 7008 7010 7011 7012 7014 I I I I I I I I I I I I I I I

Agencies

[Federal Register Volume 90, Number 15 (Friday, January 24, 2025)]
[Notices]
[Pages 8153-8154]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-01710]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1480]


Bulk Manufacturer of Controlled Substances Application: Noramco

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Noramco has applied to be registered as a bulk manufacturer of 
basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY 
INFORMATION listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants, therefore, may submit electronic comments on or 
objections to the issuance of the proposed registration on or before 
March 25, 2025. Such persons may also file a written request for a 
hearing on the application on or before March 25, 2025.

ADDRESSES: The Drug Enforcement Administration requires that all 
comments be submitted electronically through the Federal eRulemaking 
Portal, which provides the ability to type short comments directly into 
the comment field on the web page or attach a file for lengthier 
comments. Please go to https://www.regulations.gov and follow the 
online instructions at that site for submitting comments. Upon 
submission of your comment, you will receive a Comment Tracking Number. 
Please be aware that submitted comments are not instantaneously 
available for public view on https://www.regulations.gov. If you have 
received a Comment Tracking Number, your comment has been successfully 
submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on October 8, 2024, Noramco, 500 Swedes Landing Road, 
Wilmington, Delaware 19801-4417, applied to be registered as a bulk 
manufacturer of the following basic class(es) of controlled 
substance(s):

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid...............    2010  I
Marihuana...............................    7360  I
Tetrahydrocannabinols...................    7370  I
Dihydromorphine.........................    9145  I
Hydromorphinol..........................    9301  I
Amphetamine.............................    1100  II
Lisdexamfetamine........................    1205  II
Methylphenidate.........................    1724  II
Nabilone................................    7379  II
Codeine.................................    9050  II

[[Page 8154]]

 
Dihydrocodeine..........................    9120  II
Oxycodone...............................    9143  II
Hydromorphone...........................    9150  II
Hydrocodone.............................    9193  II
Methadone...............................    9250  II
Morphine................................    9300  II
Oripavine...............................    9330  II
Thebaine................................    9333  II
Opium extracts..........................    9610  II
Opium fluid extract.....................    9620  II
Opium tincture..........................    9630  II
Opium, powdered.........................    9639  II
Opium, granulated.......................    9640  II
Oxymorphone.............................    9652  II
Noroxymorphone..........................    9668  II
Tapentadol..............................    9780  II
------------------------------------------------------------------------

    The company plans to bulk manufacture the listed controlled 
substances as an Active Pharmaceutical Ingredient for supply to its 
customers. In reference to drug codes 7360 (Marihuana), and 7370 
(Tetrahydrocannabinols), the company plans to bulk manufacture these 
drugs as synthetic. No other activities for these drug codes are 
authorized for this registration.

Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2025-01710 Filed 1-23-25; 8:45 am]
BILLING CODE P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.